RARE - Ultragenyx Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
84,382
51,495
2,612
133
Cost of Revenue
4,408
1,146
1
-
Gross Profit
79,974
50,349
2,611
-
Operating Expenses
Research Development
345,912
293,998
231,644
183,204
Selling General and Administrative
154,123
127,724
99,909
64,936
Total Operating Expenses
500,035
421,722
331,553
248,140
Operating Income or Loss
-420,061
-371,373
-328,942
-248,007
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
11,066
174,276
10,604
2,168
Income Before Tax
-395,900
-197,097
-318,338
-245,839
Income Tax Expense
848
514
-16,199
35
Income from Continuing Operations
-396,748
-197,611
-302,139
-245,874
Net Income
-396,748
-197,611
-302,139
-245,874
Net Income available to common shareholders
-396,748
-197,611
-302,139
-245,874
Reported EPS
Basic
-
-3.97
-7.12
-6.21
Diluted
-
-3.97
-7.12
-6.21
Weighted average shares outstanding
Basic
-
49,775
42,453
39,587
Diluted
-
49,775
42,453
39,587
EBITDA
-
-371,373
-328,942
-248,007